For instance, the C5-inhibitor Eculizumab (Soliris) is used for systemic complement inhibition as an established treatment option for several diseases, such as atypical hemolytic uremic syndrome [174]. This evidence concerns the gene C5 and atypical hemolytic-uremic syndrome.